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Stem cell self-renewal is regulated by intrinsic mechanisms and extrinsic signals mediated via specialized microenvironments
called “niches.” The best-characterized stem cell is the hematopoietic stem cell (HSC). Self-renewal and diﬀerentiation ability of
HSC are regulated by two major elements: endosteal and vascular regulatory elements. The osteoblastic niche localized at the
inner surface of the bone cavity might serve as a reservoir for long-term HSC storage in a quiescent state. Whereas the vascular
niche, which consists of sinusoidal endothelial cell lining blood vessel, provides an environment for short-term HSC proliferation
and diﬀerentiation. Both niches act together to maintain hematopoietic homeostasis. In this paper, we provide some principles
applying tothe hematopoietic niches, which willbe usefulinthe studyand understandingofother stemcell niches.We willdiscuss
alteredmicroenvironmentsignalingleadingtomyeloidlineagedisease.Andﬁnally,wewillreviewsomedataonthedevelopmentof
acutemyeloid leukemia fromasubpopulationcalled leukemia-initiating cells (LIC),andwewilldiscuss ontheemerging evidences
supporting the inﬂuence of the microenvironment on chemotherapy resistance.
1.Introduction
Stem cells are self-renewing, and multipotent or pluripotent
cells present in diﬀerent compartments of the body, respon-
sible for the growth, maintenance, and repair of the diﬀerent
tissues. The stem cells reside in a special microenvironment;
the so-called “niche,” composed of cellular structures and
extracellular matrix in which those cells are tightly regulated
regarding their balance between maintenance of stemness,
expansion, and diﬀerentiation [1].
One of the best characterized stem cell is the hematopoi-
etic stem cells (HSC) and in 1978, Schoﬁeld proposed the
“niche” hypothesis to the HSC bone marrow (BM) microen-
vironment[2].HSCsfunctiontogeneratealifelongsupplyof
all blood cell types. The ability to reconstitute all the blood-
cell lineages in lethally irradiated mice is the most common
assay to assess the stemness in HSC [3]. And furthermore,
the maintenance of this property upon serial transplantation
shows the capability of these cells to undergo self-renewal
a n dt og i v er i s et oad i ﬀerentiated progeny at the same
time. In the past few years, the microenvironment, which
regulates HSCs, has been characterized. Within adult BM,
self-renewal and diﬀerentiation are regulated by two major
cellular components: osteoblasts and vascular endothelial
cells [4]. In this review, we provide some principles applying
to the hematopoietic niches, which will be useful in the study
and understanding of other stem cell niches. Furthermore,
theinvolvementofthenichesinthedevelopmentofleukemia
and its resistance to treatment will be described.
2 .T h eO s t eo b l a s ti cN i c h e
The concurrence of hematopoiesis and osteogenesis in BM
suggests a close relationship between bone-forming cells and
hematopoietic cells [5].2 Stem Cells International
2.1. In Vivo Evidence of the Osteoblastic Niche. In the BM,
quiescent or slow-cycling HSC have been identiﬁed close to
the endosteal surface in the trabecular bone; constituting
a reservoir of HSC that can be mobilized and restore the
hematopoiesis in response of tissue injury. Celso and col-
laborators demonstrated that after transplantation, an HSC
pool was observed in the area closest to the endosteum. They
also showed that as diﬀerentiation progressed, they homed
into distinct locations [6]. Xie and collaborators showed that
transplanted HSCs were homing to the endosteum in the
BM, which maintains and promotes HSC [7]. We have in
vivo evidence of an osteoblastic niche, which might serve as
a reservoir for HSC storage.
2.2. Secreted Factors. The bone-forming osteoblasts are cru-
cial players for the homeostasis of the hematopoietic tis-
sue with its high turnover. Indeed, osteoblasts express
several cell-signaling molecules such as BMP4, Jagged-1, and
angiopoietin-1 (Ang1), which are important for HSC self-
renewal, survival, and maintenance [8, 9]a n dh a v eb e e n
proposed to control HSC fate. Ang1 in osteoblasts interacts
withTie-2,atypeofreceptortyrosinekinasethatisexpressed
in HSC, and the Tie-2/Ang1 interaction activates β1-integrin
and N-cadherin. This enhanced adhesion contributes to the
maintenance of the stem cell quiescence. Osteopontin, a
matrixglycoproteinexpressedbytheosteoblastssupportsthe
adhesionofHSCtotheosteoblasticnicheandnegativelyreg-
ulates HSC proliferation, contributing to the maintenance of
a quiescent state [10]. Furthermore, osteoblasts in the bone
marrow produce a signiﬁcant amount of membrane-bound
stem cell factor (SCF), which has the capacity to enhance
the adhesion of HSC to stromal cells [11], suggesting that
osteoblasts can inﬂuence the adhesive characteristics of the
endostealnichebymodulatingthefunctionalstateofspeciﬁc
integrins. SCF binds and activate c-KIT, which is highly
expressed by label retaining HSC. It has been previously
shown that mutations which aﬀect the membrane bound
SCF have an inﬂuence on migration and diﬀerentiation of
diﬀerent cells including hematopoietic cells [12]. In addition
a high concentration of Ca2+ in the BM endosteal region
mediates HSC homing and lodging in the osteoblastic niche
by attracting HSCs through the calcium sensor receptor that
is highly expressed in HSCs [13].
2.3. Membrane-Bound Factors. In 2003, the work leaded
by two research groups supported the idea that osteoblasts
control the number HSC by regulating the size of the
niche. Calvi and his collaborators were able to show a
direct contact between osteoblasts and HSCs in some in
vivo studies using mutants, with increased or decreased
number of osteoblasts [14]. This study showed that an
increase in the number of osteoblasts by administration of
parathyroid hormone (PTH) produce high levels of notch
ligand Jagged-1 and increase the number of HSC. Zhang
and his collaborators showed also that it was possible
to increase or decrease the HSC number by modulating
the osteoblast number. They also showed that HSC and
osteoblasts bind each other via adhesion molecules such as
N-cadherin.AlthoughnotallosteoblastsfunctionastheHSC
niche, and a subset expressing a high level of N-Cadherin
function as a key component. These cells expressing a
high level of N-Cadherin are located in the bone surface
and named: spindle-shaped N-cadherin+CD45− osteoblas-
tic cells (SNO) [15]. Wilson and collaborators found that the
majority of HSCs/progenitors lodge in the endosteum and
attachtoN-Cadherin+osteoblasticcells15hoursaftertrans-
plantation, and HSCs harboring a c-Myc mutation increases
N-Cadherin expression, enhancing adhesion to osteoblasts
[16]. However, the fact that hematopoiesis appears normal
in N-cadherin-deﬁcient mice [17] and the localization of a
signiﬁcant amount of HSC in proximity of the sinusoidal
wallsintheBMsupportthehypothesisofanotherspecialized
microenvironment aﬀecting HSC regulation: the vascular
niche [18, 19].
3.The VascularNiche
Some evidences about the existence of a vascular niche were
already present, since in case of injury HSC can detach
from the endosteum and migrate to the vascular region
of the BM from where they restore hematopoiesis [20].
The vascular niche promotes proliferation, diﬀerentiation
of actively cycling, and short-term HSCs [21]. The most
puriﬁed HSCs, fractioned as CD150+ CD48− CD41− Lin−
cells, were found in majority to be associated with the
sinusoidal endothelium lining blood vessels, suggesting that
endothelial cells create a cellular niche for HSCs [18].
3.1. Hemangioblasts Diﬀerentiate toward HSC and Endothe-
lial Cells. A close developmental relationship between the
hematopoietic and the endothelial lineages has been shown
in the study led by Keller’s group [22]. HSCs seem to
originate from a perivascular progenitor during embryonic
development. Moreover, the presence of HSC in the yolk sac,
aorta-gonad-mesonephros(AGM)regionandvitellinearter-
ies suggests that HSCs reside and undergo hematopoiesis
in association with blood vessels. HSCs are found in close
contact with endothelial cells at any time during develop-
ment.Theendothelialcellsharvestedfromtheseregionshave
been shown to support the expansion of adult HSC LSK
(Lineage−Sca-1+c-Kit+)c e l l sin vitro [23, 24]. In contrast,
endothelial cells isolated from adult organs do not display
an HSC supportive activity in vitro [25]. These observations
support a strong embryologically interdependence between
HSCs and endothelial cells of BM sinusoids and indicate
that these cells hold distinct functional characteristics from
endothelial cells present in other tissues.
3.2. In Vivo Evidence of the Vascular Niche. On the one hand,
conditional deletion of vascular endothelial growth factor
receptor 2 (VEGF2) in adult mice, inhibits regeneration
of sinusoidal endothelial cells, and prevents hematopoietic
reconstitution in irradiated animals [26]. And, on the other
hand, thrombopoietin knock-out mice used by Raﬁi’s group
showed remarkably that CXCL12 (SDF-1, stromal cell-
derivedfactor-1)andFGF-4(ﬁbroblastgrowthfactor-4)pro-
motes megakaryocytopoiesis, restoring platelet production.Stem Cells International 3
Amongotherthings,SDF-1andFGF-4inducedupregulation
of adhesion molecules, including VLA4/VCAM1, facilitating
localization to the vascular niche [27].
3.3. Secreted Factors. The vascular niche has been shown
to produce factors important for mobilization, homing,
and engraftment of HSC, such as SDF-1 important for
mobilization, homing, and engraftment for HSCs [27]. The
role of primary human endothelial cells (PECs) in the
regulation of hematopoiesis, has been highlighted in 2006 by
a study led by Yeoh et al. [28]. This research group showed
that the cell-autonomous capacity to support homeostasis
was hidden in the presence of serum and angiogenic
factors (VEGF-A and FGF2), essential to maintain PECs
for coculture with hematopoietic stem progenitors (HSPs).
To overcome this issue, Raﬁi’s group generated a model
to study the vascular niche, where endothelial cells could
propagate, while maintaining their long-term angiogenic
proﬁle without oncogenic transformation. Indeed, they
transduced human primary endothelial cells (PECs) with the
adenovirusgene,earlyregion4encodedopenreadingframe-
1( E 4 O R F 1 )[ 29], which leads to constitutive activation of
Akt that allows for long-term culture. E4ORF1-transduced
PECs expand HSCs in vitro through secretion of stem cell
active angiocrine factors that sustain self-renewal of KLS
cells [30]. Selective activation of Akt in the endothelial
cells of adult mice increases the number of HSCs and
accelerates hematopoietic recovery after myeloablation along
with upregulation of a speciﬁc set of hematopoietic stem
and progenitor cells (HSPCs) angiocrine factors, like FGF2,
BMP4, Ang1, IGFBP2, and DHH [31].
3.4. Membrane-Bound Factors. During the bone marrow
transplantation, the ability of HSCs to “home” and engraft
in the recipient’s bone marrow requires a cascade of events
which includes speciﬁc molecular recognition. Adhesion
molecules on the HSCs involved in the process of rolling are
VLA4 (CD49d), LFA-1 (CD11a), and hyaluronan binding-
cellular adhesion molecule (HCAM/CD44) whereas the
complementary binding partners on the BM endothelial
cells are VCAM-1, ICAM-1 (CD54), and E- and P-selectin
(CD62E and CD62P) [32]. The notch signaling pathway
involves the activity of notch transmembrane receptors 1, 3,
and4,whichinteractwithmembrane-boundligands,Delta1,
2, and 4, and Serrate/Jagged-1 and 2. Ligand binding induces
proteolytic cleavage of notch receptor by a gamma-secretase
complex causing the subsequent translocation of the notch
intracellular domain (NICD) to the nucleus, where it will
activate the transcription of downstream target genes such
as Hes1 (hairy enhancer of split homolog-1) and Hey1 and
Hey2 (Hes-related protein) [33]. Notch-1 is expressed on
LT-HSCs and maintains HSCs in an undiﬀerentiated state
[14, 34, 35]. Overexpression of the intracellular domain of
notch enhances HSC self-renewal [36] whereas loss of notch
signaling impairs the maintenance of HSCs both in vitro
and in vivo [14, 37]. Butler and his collaborators blocked
angiogenic pathways, which led to inhibition of notch ligand
expression and a decrease of LT-HSCs expansion [30].
Altogether, these observations suggest that endothelial cells
enhance proliferation of HSCs and play an important role in
maintaining the pool.
4. Common Components and Differences
CXCL12/CXCR4 signaling plays important roles in HSC
traﬃcking and HSC mobilization. Sugiyama and his collabo-
rators [38] demonstrated that HSCs were speciﬁcally located
adjacent to cells expressing a high level of CXCL12, which
surrounded the sinusoidal endothelial cells. They named
these cells CXCL12-abundant reticular cells (CAR). They
also demonstrated that a depletion of CXCR4 led to a reduc-
tion of HSC pool. Selective short-term ablation of CAR cells
within bone marrow has suggested that they play a crucial
role in proliferation, maintenance in an undiﬀerentiated
state. HSCs have been shown to be associated with CAR
cells in the sinusoidal region and are located between CAR
and osteoblastic cells in the endosteal region, suggesting that
those cells might be an important component of both the
osteoblastic and the vascular niches in adult BM.
The major diﬀerence between both microenvironments
is the oxygen level. Higher in the vascular niche than in
the osteoblastic niche under hypoxia, HSCs would move to
the vascular niche and resume then cell cycle in order to
restore hematopoiesis [39]. HSCs can then come back to the
osteoblastic niche where they would be maintained in the G0
state once again [40]. The role of the hypoxia has recently
been demonstrated. Using a transgenic VEGFδ/δ mice model
where the hypoxia response element in the VEGF promoter
is enable to bind HIF; the authors demonstrated impairment
of HSC function and conﬁrmed that one important role of
the hypoxic niche is to provide HSCs intrinsically with the
survival factor VEGFA [41].
The osteoblastic niche localized at the inner surface of
the bone cavity and with abundant osteoblasts, might serve
as a reservoir for long-term HSC storage in a quiescent state.
Whereas the vascular niche, which consists of sinusoidal
endothelial cell lining blood vessel, provides an environment
for short-term HSC proliferation and diﬀerentiation. Both
niches act together to maintain hematopoietic homeostasis
or restore it after damage.
5. Altered Microenvironment Leads to
Myeloid LineageDiseases
Several studies have provided insights into the role of
alteredmicroenvironmentsignalingleadingtomyeloﬁbrosis,
myeloma,andmyelodysplasticsyndromes.Ithasbeenshown
that alterations of the microenvironment, such as decreased
expression of the retinoblastoma gene in cells of the BM
microenvironment, can induce a myeloproliferative disorder
[42]. Latillade reviews key data suggesting that an imbalance
between endosteal and vascular niches may be important in
idiopathic disorder characterized by bone marrow ﬁbrosis
(primary myeloﬁbrosis), leading to the development of
clonal stem cell proliferation [43].4 Stem Cells International
Wnt signaling pathway plays a critical role in the patho-
genesis of myeloma. A dramatic eﬀect of directly targeting
this pathway in osteoblasts has been clearly demonstrated,
showing that it could prevent in vivo, the development of
myeloma disease within bone. Increasing Wnt signaling in
the bone marrow microenvironment inhibits the develop-
ment of myeloma and reduces tumor burden in bone in
vivo [44]. Microenvironment perturbations play also a role
in myelodysplastic syndromes (MDS). Raaijmakers and his
collaborators have developed transgenic mice with a dicer
knock out only in osteoblast progenitor to investigate if
altered niche caused myelodysplasia [45]. Although dicer,
which encodes a critical enzyme in the formation of
microRNAs, was not deleted from the hematopoietic cells,
these mice developed a form of myelodysplastic disease. To
identify the mechanism by which dicer deletion in osteoblast
progenitors may cause MDS, the investigators performed
gene expression analysis. Diﬀerentially expressed genes and
pathways included cytokines and stress response pathways,
including signiﬁcant downregulation of the Shwachman-
Bodian-Diamond (sbds) gene, which is linked to the human
Shwachman-Diamond syndrome. Although the mechanism
linking dicer deletion to sbds expression is not clear, the
investigators showed that knockdown of just the Sbds gene
in osteoblast progenitors reproduces much of the MDS
phenotype.
6. Consequences of the Niches in
the Development of Leukemia and
Resistance to Treatment
AML is the most common leukemia according to the SEER
program of the National Cancer institute. AML is a cancer of
the myeloid line of blood cells. AML is a stem cell disease
with a hierarchy comparable to normal hematopoiesis. In
parallel with leukemogenesis events, the niche provides an
environment with signals that favor cell proliferation and
growth. Although, recent line of evidences suggest that the
tumor cells are heterogeneous and indicate that only a
fraction of the tumor cells “the leukemia-initiating cells”
(LIC) are mostly in a quiescent state and are responsible for
the maintenance of the neoplasm [46].
6.1.InVivo EvidenceofNichesforLeukemiaCells. Ithasbeen
demonstrated that the normal hematopoiesis disappear in
leukemic patients, disturbing the BM niches [47]. Both
niches play a critical role in the survival, proliferation, and
diﬀerentiation of LSC. The group led by Ninomiya showed
the homing proliferation and survival sites of leukemia cells
in immunodeﬁciencies mice. Indeed, when transplanted,
leukemia cells initially localized on the surface of the
osteoblasts in the inner vascular and diaphyseal region.
Under administration of a high dose of cytarabine leukemia
cells clustered and adhered to the blood vessels suggesting
that leukemia cells receive antiapoptotic signals from vas-
cular niche as well [48]. The molecular mechanisms for
maintaining quiescence of normal HSCs may also facilitate
LSC survival.
6.2. Secreted Factors. Similar to regeneration of hematopoi-
etic cells, leukemic cells may also take advantage of pro-
survival signals conveyed by the osteoblastic and vascular
niches to support their proliferation and invasive potential.
Osteoblasts provide a source of osteopontin and SDF-1,
which may induce migration of CXCR4-expressing LSCs
towardstheosteoblasticniche.TheinteractionbetweenSDF-
1 and its receptor on leukemic progenitor cells contributes
to their homing to the BM microenvironment. Endothelial
cells are protective of leukemia and increased levels of angio-
genesis in the BM of AML patients have been reported [49].
Moreover VEGF acts as an autocrine and paracrine growth
factor in some AMLs that express the VEGFR2 [50, 51].
VEGF is a hypoxia-inducible growth factor that stimulates
the formation of new blood vessels. As an adaptive response
tohypoxia,newvesselsaregeneratedbyangiogenesisandthe
proliferationofendothelialcellsisstimulated.Bysecretionof
cytokines, including IL-6, IL-3, G-CSF, GM-CSF, and nitric
oxide (NO) [52,53],endothelialcellswereshowntopromote
leukemic proliferation, suggesting that activated angiogenic
endothelial cells could provoke leukemic cell growth through
paracrine signaling.
6.3. Membrane Bound Factors. The attachment of AML cells
to the BM microenvironment through interaction between
v e r yl a t ea n t i g e n - 4o nl e u k e m i cc e l l sa n dﬁ b r o n e c t i no n
stromal cells has been shown to be crucial for the persistence
of minimal residual disease in AML [54]. CXCR4 levels are
signiﬁcantly elevated in leukemic cells from patients with
AML [55] and CXCR4 expression is associated with poor
outcome [56, 57]. It has been shown that administration
of anti-CXCR4 antibody to a NOD/SCID mice engraft with
primary AML cells resulted in a dramatic decrease in the
level of human AML cells in diﬀerent sites/BM, blood, and
spleen. Interestingly, the levels of normal human progenitor
cells were not aﬀected [58]. Dick and colleagues showed that
anti-CD44 antibody-treated NOD/SCID mice transplanted
withAMLexhibitedasigniﬁcantlylowerrateofdiseaseonset
[59]. This indicates that CD44 is essential for the homing
and engraftment of the LSC to the niche. To summarize the
role of the microenvironment in leukemia and its normal
physiologic role in supporting HSC it has been summarized
in Figure 1.
6.4. Microenvironment and Resistance to Chemotherapy.
From a clinical perspective, it has been demonstrated that
LSCs are substantially more resistant to standard forms of
chemotherapy than bulk leukemia populations. In order to
optimize the treatment, it is mandatory to characterize the
interaction of leukemic cells with their microenvironment in
the bone marrow. The tumor microenvironment is increas-
ingly being recognized as a critical factor in mediating drug
resistance. Resistance may occur through the soluble release
of growth factors and by contact-dependent mechanisms
via cell-cell and cell-extracellular matrix interactions. The
term,celladhesion-mediateddrugresistance(CAM-DR)has
been used to describe the phenotype in which interaction of
malignant cells with stroma confers resistance to chemother-
apy. CAM-DR has been described in vitro for both primaryStem Cells International 5
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Figure 1: Schematic representation of the (a) HSC, normal stem cell and (b) LIC, leukemia-initiating cell interactions with the
microenvironment. Niches provide support for self-renewal, quiescence, homing, enfrafment, and proliferation. As shown, HSCs and
LSC reside in the osteoblastic or vascular niche. HSCs and LSC interact with multiple cell types (OB, OC, EC, CAR, MSC) within the
BM microenvironment. Although schematically represented separately, the endosteal, and vascular niches are physically and functionally
mutually involved. Candidate niche mechanisms, which regulate HSC function are also shown, including Jagged/notch, SDF1/CXCR4,
SCF/c-Kit signaling. LIC quiescence, survival, and expansion are inﬂuenced by receptor kinases, adhesive receptors and signaling via matrix
mediated/bound chemokines and cytokines (IL6, G-CSF, GM-CSF, KIT L, NOTCH L). LIC may secrete substance like SCF, inﬁltrate the
niches, and take advantage of the normal hemostatic process, which enhances self-renewal and proliferation. Growth factor and other
adhesionreceptorssignalscanbetargetedtoovercomechemoresistance.Oxygenlevel,higherinthevascularnichethantheosteoblasticniche
under hypoxia. LIC proliferation results in expansion of hypoxic niche. HSC: hematopoietic Stem Cell, OPN: osteopontin, LIC: leukemia-
initiating Cell, N-Cad: N-Cadherin, OC: osteoclast, VLA-4: very late antigen 4, OB: osteoblast, VEGFR: vascular endothelial growth factor
receptor, TB: trabecular bone, SDF1: stromal growth factor 1, SCF: stem cell factor, Ang1: angiopoietin 1, HA: hyaluronic acid, ECM:
extracellular matrix.
tumors and cell lines derived from several hematologic
malignancies [60]. There is an increase in neovessel density
in the marrow of patients with leukemia; suggesting that
crosstalk between leukemic and the activated vascular niche
contribute to disease progression. Dr. Raﬁi and others have
shown that inhibition of angiogenesis eﬀectively blocks the
progression of subsets of leukemias. Clinical trials have been
initiated to evaluate the use of antiangiogenic agents in
combinationwithstandardchemotherapytotreatleukemias.
The hematopoietic system continues to evolve as a mod-
el; however, concerning the microenvironment, numerous
criticalissuesremaintobeaddressed.Acriticalrolefornotch
in hematopoiesis was initially suggested after detection of the
human NOTCH-1 gene in CD34+ or CD34+ lin− human
hematopoietic precursors [61]. Then several reports [36, 62,
63] have shown that NOTCH-1 plays a key regulatory role in
hematopoiesis and suggest that notch ligands will be useful
reagents for improving ex vivo culture of stem/progenitor
cells. In 2010, a research group leaded by Bernstein reports
the development of an optimized, clinically feasible method-
ology for generating cord blood stem/progenitor cells for
clinical evaluation. Ex vivo culture of CD34+ cord blood
stem/progenitor cells in the presence of notch ligand resulted
in a greater than 100-fold increase in CD34+ cells that6 Stem Cells International
repopulate immunodeﬁcient mice. This work was the ﬁrst
demonstration of rapid hematopoietic engraftment derived
from ex vivo expanded hematopoietic progenitors. A recent
study has demonstrated for the ﬁrst time that the activation
of notch pathway may indicate a poor prognosis in AML
[64]. Especially, NOTCH-1, Jagged-1 and Delta1 expression
may be relevant prognostic markers in intermediate risk
AML. Nowadays, the most clinically arguably advanced
approach for inﬂuencing leukemia microenvironment is
targetingtheangiogenesis.Forexample,therapiescombining
a monoclonal antibody neutralizing VEGF, bevacizumab
withotherchemotherapiesas(cytarabineandmitoxantrone)
improve the overall response rate of relapse and refractory
AML [65]. Recently, new antiangiogenic agents are in use;
among them, tyrosine kinase inhibitors (such as sorafenib
for targeting VEGFR) and anticytokine drugs (such as
thalidomide). On the one hand, those therapies can aﬀect
vascular endothelial niche but on the other hand, they may
induce chemoresistance through the increase of hypoxia.
In conclusion, targeting leukemic cells and cells in their
surrounding microenvironment might be useful to observe
a reduction of the leukemic burden. Going forward, it is
challenging to revisit many of the concepts derived from
work in the blood ﬁeld in other organ systems. This will
probably increase our knowledge on the network controlling
self-renewal and diﬀerentiation, the hallmarks of stem cells.
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